BPTSY Stock - Biophytis S.A.
Unlock GoAI Insights for BPTSY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-803,000 | $-484,000 | $-311,000 | $-280,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-8,500,000 | $-14,333,000 | $-23,272,000 | $-26,815,000 | $-13,942,000 |
| Net Income | $-10,379,000 | $-17,026,000 | $-24,216,000 | $-31,163,000 | $-25,517,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-2.00 | $-125.50 | $-560.60 | $-1056.40 | $-1724.10 |
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
Visit WebsiteEarnings History & Surprises
BPTSYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Oct 30, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q2 2025 | May 27, 2025 | — | — | — | — |
Q3 2024 | Sep 30, 2024 | $-1.96 | — | — | — |
Q3 2024 | Sep 27, 2024 | — | $-0.83 | — | — |
Q2 2024 | Apr 8, 2024 | $-12.90 | $-2.44 | +81.1% | ✓ BEAT |
Q2 2024 | Apr 2, 2024 | — | $-0.83 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-2.44 | — | — |
Q2 2023 | Jun 30, 2023 | $-20.00 | $-4.74 | +76.3% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | — | $-4.74 | — | — |
Q4 2022 | Dec 31, 2022 | $-48.00 | $-11.71 | +75.6% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | — | $-11.71 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-16.78 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-16.78 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-28.47 | — | — |
Q3 2021 | Sep 30, 2021 | $-40.00 | $-28.47 | +28.8% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | — | $-23.93 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-23.93 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-28.57 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-28.57 | — | — |
Latest News
Frequently Asked Questions about BPTSY
What is BPTSY's current stock price?
What is the analyst price target for BPTSY?
What sector is Biophytis S.A. in?
What is BPTSY's market cap?
Does BPTSY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to BPTSY for comparison